---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-23-000048"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2023-08-07T23:59:59+00:00"
generated_at: "2026-06-12T04:26:25.018070+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Keros Q2 net loss $37.5M, cash $322M; plans KER-065 Phase 1 in DMD for Q1 2024

## Summary
- Net loss of $37.5M in Q2 2023 vs $27.3M in Q2 2022, driven by increased R&D spend.
- R&D expenses $32.5M (+$9.3M YoY) on pipeline advancement and manufacturing.
- Cash and equivalents $322.0M as of June 30, 2023; expects runway into Q4 2025.
- Phase 2 TROPOS trial of KER-012 in PAH cleared by FDA; webcast on trial design Aug 8.
- KER-065 for Duchenne muscular dystrophy to start Phase 1 in healthy volunteers Q1 2024.

## SEC filing metadata
- accession: 0001664710-23-000048
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2023-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000048/0001664710-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000048/kros-20230807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-23-000048
- JSON: https://secwatch.observer/filing/0001664710-23-000048.json
- Plain text: https://secwatch.observer/filing/0001664710-23-000048.txt

## Key facts
- Earnings Releases
  Keros Therapeutics, Inc. reported the quarter ended June 30, 2023 results: net income a net loss of $37.5 million.
  - Period: the quarter ended June 30, 2023
  - Net income: a net loss of $37.5 million
  - Result: reported results
  source text: Keros Therapeutics, Inc. (the “Company”) issued a press release announcing its recent business highlights and financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1664710/000166471023000048/0001664710-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.